SCHEMBL3257828

SCHEMBL3257828

c1ccc(-c2ccc(-c3ccsc3)cc2)nc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 6/20 0.55
CYP2B6 P20813 3/20 0.55
CYP2E1 P05181 2/20 0.55
KDM4E B2RXH2 3/20 0.46
CYP1A2 P05177 2/20 0.46
LMNA P02545 1/20 0.46
POLB P06746 1/20 0.46
CCR1 P32246 1/20 0.46
CCR5 P51681 1/20 0.46
CCR8 P51685 1/20 0.46
METAP1 P53582 1/20 0.46
BLM P54132 1/20 0.46
HIF1A Q16665 1/20 0.46
DOHH Q9BU89 1/20 0.46
P4HTM Q9NXG6 1/20 0.46
CYP17A1 P05093 1/20 0.46
CYP11B1 P15538 1/20 0.46
CYP11B2 P19099 1/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL597347 0.90 KDM4E (0.52) CYP2A6CYP2B6CYP2E1KDM4ECYP1A2
SCHEMBL29723603 0.90 KDM4E (0.52) CYP2A6CYP2B6CYP2E1KDM4ECYP1A2
SCHEMBL29984274 0.82 KDM4E (0.68) CYP2A6KDM4ECYP1A2LMNAPOLB
SCHEMBL13458076 0.82 KDM4E (0.68) CYP2A6KDM4ECYP1A2LMNAPOLB
SCHEMBL4359878 0.81 CCR1 (0.51) CYP2A6CYP2B6CYP2E1KDM4ECYP1A2
SCHEMBL30989133 0.79 KDM4E (0.72) CYP2A6KDM4ECYP1A2LMNAPOLB
SCHEMBL30989132 0.79 KDM4E (0.72) CYP2A6KDM4ECYP1A2LMNAPOLB
SCHEMBL1566968 0.79 KDM4E (0.72) CYP2A6KDM4ECYP1A2LMNAPOLB
SCHEMBL28328948 0.78 KDM4E (0.56) CYP2A6KDM4ECYP1A2LMNAPOLB
SCHEMBL21173034 0.78 KDM4E (0.62) CYP2A6KDM4ECYP1A2LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2168576-A2 New utilities of tricyclic compounds Shionogi & Co., Ltd. (JP) 2010-03-31 EP disclosed
EP-2168576-A2 New utilities of tricyclic compounds Shionogi & Co., Ltd. (JP) 2010-03-31 EP disclosed
US-20080318958-A1 New utilities of tricyclic compounds ISHIZUKA NATSUKI 2008-12-25 US disclosed
US-20080318958-A1 New utilities of tricyclic compounds ISHIZUKA NATSUKI 2008-12-25 US disclosed
US-20080318958-A1 New utilities of tricyclic compounds ISHIZUKA NATSUKI 2008-12-25 US disclosed
US-20040235877-A1 Novel use of tricyclic compound SHIONOGI & CO., LTD. (JP) 2004-11-25 US disclosed
EP-1426046-A1 NOVEL USE OF TRICYCLIC COMPOUND SHIONOGI & CO., LTD. (JP) 2004-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235877-A1 Novel use of tricyclic compound APOB, PON1, APOL1 CYP2A6 180/4885CYP2B6 167/4885CYP2E1 131/4885
US-20080318958-A1 New utilities of tricyclic compounds APOB, PON1, APOL1 CYP2A6 119/4885CYP2B6 112/4885CYP2E1 169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.